Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 26-36

  Jacobs, Anna C ^a   DiDone, Louis ^b   Jobson, Jennielle ^a   Sofia, Madeline K ^a   Krysan, Damian ^a,b   Dunman, Paul M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; ERYTHROMYCIN; KANAMYCIN; LINEZOLID; MEROPENEM; MINOCYCLINE; SULFAMETHOXAZOLE; TAMOXIFEN; TERFENADINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOLYSIS; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ADENYLATE KINASE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOFILMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HIGH-THROUGHPUT SCREENING ASSAYS; LARVA; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MOTHS; TAMOXIFEN; TERFENADINE;

EID: 84872022611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01640-12     Document Type: Article

References (45)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
2. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197:1079-1081.
3. Talbot GH, Bradley J, Edwards, JE, Jr, Gilbert D, Scheld M, Bartlett JG. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42:657-668.
4. Silver LL. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24:71-109.
5. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
6. Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore G, Tenover FC, Cody S, Jernigan DB. 2005. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J. Med. 352:468-475.
7. Gillaspy AF, Hickmon SG, Skinner RA, Thomas JR, Nelson CL, Smeltzer MS. 1995. Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect. Immun. 63:3373-3380.
8. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P. 1988. Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J. Bacteriol. 170:4365-4372.
9. Pomakova DK, Hsiao CB, Beanan JM, Olson R, MacDonald U, Keynan Y, Russo TA. 2012. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and underrecognized pathogenic variant. Eur. J. Clin. Microbiol. Infect. Dis. 31:981-989.
10. Jacobs AC, Hood I, Boyd KL, Olson PD, Morrison JM, Carson S, Sayood K, Iwen PC, Skaar EP, Dunman PM. 2010. Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect. Immun. 78:1952-1962.
11. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J. Gen. Microbiol. 13:572-581.
12. Hindler JF. 2010. Antimicrobial susceptibility testing, section 5. Clinical microbiology procedures handbook, vol 1. American Society for Microbiology, Washington, DC.
13. Beenken KE, Blevins JS, Smeltzer MS. 2003. Mutation of sarA in Staphylococcus aureus limits biofilm formation. Infect. Immun. 71:4206-4211.
14. Musken M, Di Fiore S, Romling U, Haussler S. 2010. A 96-well-plate-based optical method for the quantitative and qualitative evaluation of Pseudomonas aeruginosa biofilm formation and its application to susceptibility testing. Nat. Protoc. 5:1460-1469.
15. Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. 2003. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology 149:3473-3484.
16. Lebreton F, Le Bras F, Reffuveille F, Ladjouzi R, Giard JC, Leclercq R, Cattoir V. 2011. Galleria mellonella as a model for studying Enterococcus faecium host persistence. J. Mol. Microbiol. Biotechnol. 21:191-196.
17. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering, RC, Jr, Eliopoulos GM. 2009. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 199:532-536.
18. Cameron-Clarke A, Hulse GA, Clifton L, Cantrell IC. 2003. The use of adenylate kinase measurement to determine the causes of lysis in lager yeast. J. Am. Soc. Brew. Chem. 61:152-156.
19. Corbitt AJ, Bennion N, Forsythe SJ. 2000. Adenylate kinase amplification of ATP bioluminescence for hygiene monitoring in the food and beverage industry. Lett. Appl. Microbiol. 30:443-447.
20. Squirrell D, Murphy M. 1997. Rapid detection of very low numbers of micro-organism using adenylate kinase as a cell marker, p 107-113. In Stanley P, Smither R, Simpson W (ed), A practical guide to industrial uses of ATP-luminescence in rapid microbiology. Cara Technology Limited, Leatherhead, United Kingdom.
21. DiDone L, Scrimale T, Baxter BK, Krysan DJ. 2010. A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis. Nat. Protoc. 5:1107-1114.
22. Krysan DJ, Didone L. 2008. A high-throughput screening assay for small molecules that disrupt yeast cell integrity. J. Biomol. Screen. 13:657-664.
23. Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr, TR, Jr, Moeck G. 2009. Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes. Int. J. Antimicrob. Agents 34:550-554.
24. McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Jr, Moeck G. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63:1191-1199.
25. Nielsen EI, Viberg A, Lowdin E, Cars O, Karlsson MO, Sandstrom M. 2007. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob. Agents Chemother. 51:128-136.
26. Carleton J, Phair JP. 1972. The slow bactericidal effect of tetracycline and minocycline on wall-defective staphylococcus. J. Infect. Dis. 126:457-459.
27. Li RC, Lee SW, Kong CH. 1997. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. J. Antimicrob. Chemother. 40:39-45.
28. Benoit MR, Conant CG, Ionescu-Zanetti C, Schwartz M, Matin A. 2010. New device for high-throughput viability screening of flow biofilms. Appl. Environ. Microbiol. 76:4136-4142.
29. Perez LM, Alvarez BL, Codony F, Fittipaldi M, Adrados B, Penuela G, Morato J. 2010. A new microtitre plate screening method for evaluating the viability of aerobic respiring bacteria in high surface biofilms. Lett. Appl. Microbiol. 51:331-337.
30. An WF, Tolliday N. 2010. Cell-based assays for high-throughput screening. Mol. Biotechnol. 45:180-186.
31. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
32. Oliva B, O'Neill AJ, Miller K, Stubbings W, Chopra I. 2004. Antistaphylococcal activity and mode of action of clofazimine. J. Antimicrob. Chemother. 53:435-440.
33. Markaryan A, Zaborina O, Punj V, Chakrabarty AM. 2001. Adenylate kinase as a virulence factor of Pseudomonas aeruginosa. J. Bacteriol. 183:3345-3352.
34. Cooksey RC, Crawford JT, Jacobs WR, Jr, Shinnick TM. 1993. A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob. Agents Chemother. 37:1348-1352.
35. Kirsch DR, Lai MH, McCullough J, Gillum AM. 1991. The use of beta-galactosidase gene fusions to screen for antibacterial antibiotics. J. Antibiot. (Tokyo) 44:210-217.
36. Srivastava R, Deb DK, Srivastava KK, Locht C, Srivastava BS. 1998. Green fluorescent protein as a reporter in rapid screening of antituberculosis compounds in vitro and in macrophages. Biochem. Biophys. Res. Commun. 253:431-436.
37. Wermuth CG. 2006. Selective optimization of side activities: the SOSA approach. Drug Discov. Today 11:160-164.
38. Woosley RL, Chen Y, Freiman JP, Gillis RA. 1993. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
39. Reck F, Alm R, Brassil P, Newman J, Dejonge B, Eyermann CJ, Breault G, Breen J, Comita-Prevoir J, Cronin M, Davis H, Ehmann D, Galullo V, Geng B, Grebe T, Morningstar M, Walker P, Hayter B, Fisher S. 2011. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity. J. Med. Chem. 54:7834-7847.
40. Morello KC, Wurz GT, DeGregorio MW. 2003. Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42:361-372.
41. Dolan K, S. Montgomery, Buchheit B, Didone L, Wellington M, Krysan DJ. 2009. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53:3337-3346.
42. Wiseman H, Cannon M, Arnstein HR. 1989. Observation and significance of growth inhibition of Saccharomyces cerevisiae (A224A) by the anti-oestrogen drug tamoxifen. Biochem. Soc. Trans. 17:1038-1039.
43. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A. 1995. Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem. Pharmacol. 50:723-726.
44. Luxo C, Jurado AS, Madeira VM, Silva MT. 2003. Tamoxifen induces ultrastructural alterations in membranes of Bacillus stearothermophilus. Toxicol. In Vitro 17:623-628.
45. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP. 2006. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. 8:47-52.